How tirzepatide affects glucagon — and why that matters for weight loss

Step 1, what glucagon normally does in the body

Glucagon is a peptide hormone released by alpha cells in the pancreas, chiefly when blood glucose falls. Its job is to signal the liver to release stored glucose, keeping levels stable between meals and overnight. That is useful in moderation. In people with excess weight or type 2 diabetes, glucagon secretion can become dysregulated: levels stay elevated even after eating, which pushes blood glucose higher than it needs to be and can drive ongoing hunger signals. Getting glucagon under tighter control is therefore one of the targets that modern weight-management medicines aim at, and it is where tirzepatide's dual mechanism becomes relevant.

For a broader grounding in how tirzepatide works, the GLP-1 and tirzepatide overview covers the receptor science in plain language.

Step 2, how GLP-1 receptor activation damps down glucagon

GLP-1 (glucagon-like peptide-1) is released from the gut after eating. One of its key actions is to suppress glucagon secretion from the pancreas in a glucose-dependent way, meaning it only does this when glucose is already present, which reduces the risk of blood sugar falling too low. Tirzepatide binds to GLP-1 receptors and replicates this suppression. The result is that after meals, glucagon stays lower than it would otherwise, the liver releases less stored glucose, and insulin can work more efficiently. Appetite also falls, partly because GLP-1 receptor activation slows gastric emptying, so food moves through the stomach more gradually and fullness signals last longer. The tirzepatide medicine page has a plain summary of these effects for anyone reading about it for the first time.

According to the NHS medicines page for tirzepatide, common effects of the medicine include reduced appetite and slower gastric emptying, both of which follow directly from this receptor activity.

Step 3, the GIP layer and what it adds to glucagon control

GIP (glucose-dependent insulinotropic polypeptide) is the second receptor tirzepatide activates, and its relationship with glucagon is more nuanced. In healthy people, GIP tends to suppress glucagon after meals, much like GLP-1. In people with obesity or type 2 diabetes, this response is blunted, GIP's glucagon-suppressing effect is reduced. Tirzepatide's GIP agonism appears to help restore this response, working alongside the GLP-1 pathway rather than duplicating it. Beyond the pancreas, GIP receptors exist on fat cells, and activation there seems to influence how fat is stored and mobilised. This is one reason researchers believe the dual mechanism produces greater average weight loss than GLP-1 agonism alone, as the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, suggested when comparing tirzepatide directly with semaglutide 2.4 mg. That said, the full picture of GIP's role in human weight regulation is still being studied, and you can read more about the formulation specifics on the tirzepatide l page, which covers that area in more detail. You can also explore how the two medicines compare in practice on the Mounjaro vs tirzepatide guidance page.

Step 4, what this means practically, including eligibility and how treatment is structured

Tirzepatide is licensed in the UK under the brand name Mounjaro, as a once-weekly subcutaneous injection. Treatment starts at 2.5 mg (a dose designed to let your system adjust) and is titrated upward by the prescriber, typically in four-week steps, through 5, 7.5, 10, 12.5 and up to 15 mg. The pen lives in the fridge between doses, and each one delivers four weekly injections before you need a new pen. Private eligibility broadly covers adults with a BMI of 30 or above, or 27 or above with a weight-related condition such as high blood pressure, type 2 diabetes or dyslipidaemia; a prescriber assesses the full picture, not the number alone. Details on how costs vary across the private market are covered on the Mounjaro UK price context page, which is worth reading before you decide where to get treatment. The GLP and tirzepatide eligibility page goes further on who the medicine is licensed for.

Because these are prescription-only medicines, a registered prescriber needs to review your health information before any treatment can be issued. NICE's appraisal of tirzepatide, TA1026, sets out the clinical evidence base and NHS eligibility criteria for those who may qualify through that route. If you think tirzepatide might be right for you, checking your eligibility through a regulated service is the sensible next step.